

**UGANDA INACTIVATED POLIO VACCINE (IPV) SUPPORT**  
This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Uganda															
<b>2. Grant Number:</b> 1518-UGA-25b-X / 15-UGA-08h-Y															
<b>3. Date of Decision Letter:</b> 6 March 2015 (this Decision Letter replaces the previous one for IPV issued on 15 September 2014)															
<b>4. Date of the Partnership Framework Agreement:</b> 28 June 2013															
<b>5. Programme Title:</b> NVS, IPV Routine															
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)															
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID															
<b>8. Programme Duration<sup>2</sup>:</b> 2015 – 2018															
<b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b> <i>Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i> <table border="1" data-bbox="327 913 1327 1064"> <thead> <tr> <th></th> <th>2015</th> <th>2016</th> <th>2017</th> <th>Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$ 2,349,500</td> <td>US\$ 3,572,500</td> <td>US\$2,857,500</td> <td>US\$8,779,500</td> </tr> </tbody> </table>		2015	2016	2017	Total <sup>3</sup>	Programme Budget (US\$)	US\$ 2,349,500	US\$ 3,572,500	US\$2,857,500	US\$8,779,500					
	2015	2016	2017	Total <sup>3</sup>											
Programme Budget (US\$)	US\$ 2,349,500	US\$ 3,572,500	US\$2,857,500	US\$8,779,500											
<b>10. Vaccine Introduction Grant:</b> US\$1,356,500 (amount disbursed on 3 March 2015).															
<b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup></b> The Annual Amounts for 2015 and 2016 have been amended. <table border="1" data-bbox="360 1236 1279 1444"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2015</th> <th>2016</th> </tr> </thead> <tbody> <tr> <td>Number of IPV vaccines doses</td> <td>1,147,800</td> <td>1,740,100</td> </tr> <tr> <td>Number of AD syringes</td> <td>958,900</td> <td>1,650,900</td> </tr> <tr> <td>Number of safety boxes</td> <td>10,550</td> <td>18,175</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$2,349,500</td> <td>US\$3,572,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2015	2016	Number of IPV vaccines doses	1,147,800	1,740,100	Number of AD syringes	958,900	1,650,900	Number of safety boxes	10,550	18,175	Annual Amounts (US\$)	US\$2,349,500	US\$3,572,500
Type of supplies to be purchased with Gavi funds in each year	2015	2016													
Number of IPV vaccines doses	1,147,800	1,740,100													
Number of AD syringes	958,900	1,650,900													
Number of safety boxes	10,550	18,175													
Annual Amounts (US\$)	US\$2,349,500	US\$3,572,500													
<b>12. Procurement agency:</b> UNICEF															
<b>13. Self-procurement:</b> Not applicable															
<b>14. Co-financing obligations:</b> Gavi's usual co-financing requirements do not apply to IPV. However, Uganda is encouraged to contribute to vaccine and/or supply costs for IPV.															
<b>15. Operational support for campaigns:</b> Not applicable															

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<sup>4</sup> This is the amount that Gavi has approved.

**16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:**

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat

**17. Financial Clarifications:** Not applicable

**18. Other conditions:**

If Uganda envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Uganda.

REMINDER: Under the Partnership Framework Agreement, "the government shall maintain, where available at a reasonable cost, all risk property insurance on the Programme assets (including vaccines and vaccine related supplies) and comprehensive general liability insurance with financially sound and reputable insurance companies". In this context, kindly provide Gavi with a copy of such insurance policy to ensure compliance with this requirement.

**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes

6 March 2015